March 31, 2015

VentureWire

Thrasos Therapeutics Raises $21M, Advances Drug to Prevent Acute Kidney Injury

Thrasos Therapeutics Inc. has raised a $21 million Series D financing to make acute kidney injury a less-common complication of heart surgery.

Acute kidney injury can lead to increased risk of illness and death, according to the National Kidney Foundation . It occurs in 20% to 25% of cardiac surgeries, Thrasos Chief Executive Richard Andrews said. Some cardiac-surgery patients are at even higher risk, including the elderly and people who already have chronic kidney disease, he said....

Read more: http://pevc.dowjones.com/article?an=DJFVW00120150331eb3vow0l5&from=NL&mod=djem_DJFVW&pid=32&ReturnUrl=http%3a%2f%2fpevc.dowjones.com%2farticle%3fan%3dDJFVW00120150331eb3vow0l5%26from%3dNL%26mod%3ddjem_DJFVW%26pid%3d32